Vorhofflimmerablation und Antikoagulation – Welches Patientenkollektiv kann profitieren?

Bernd-Dieter Gonska

doi:10.1055/s-0034-1377056

Der Klinikarzt, Table of Contents

Der Klinikarzt 2014; 43(S 01): 48-52
DOI: 10.1055/s-0034-1377056

Schwerpunkt

Vorhofflimmerablation und Antikoagulation – Welches Patientenkollektiv kann profitieren?

Atrial fibrillation and anticoagulation – Which patients might benefit most?

Bernd-Dieter Gonska

¹St. Vincentius-Kliniken Karlsruhe, Medizinische Klinik III, Kardiologie, Intensivmedizin, Angiologie, Akademisches Lehrkrankenhaus der Universität Freiburg

› Author Affiliations

Abstract

Zusammenfassung

Die Antikoagulation bei Vorhofflimmern richtet sich nach dem CHA₂DS₂-VASc-Score. Nach einer Katheterablation ist die Antikoagulation abhängig von dem vorbestehenden CHA₂DS₂-VASc-Score. Für die orale Antikoagulation stehen ausschließlich die Coumadine und die Direkten Oralen Antikoagulantien zur Verfügung. Die Ablation ist mit einer hohen Erfolgsrate bei symptomatischen Patienten mit paroxysmalem Vorhofflimmern durchführbar.

Summary

Anticoagulation after catheter ablation of atrial fibrillation is depending on the preexisting CHA₂DS₂-VASc-Score. Only Coumadines and DOACs (Direct Oral Anticoagulants) should be administered in patients with atrial fibrillation. Due to the guidelines catheter ablation is prooving to be effective in symptomatic patients with paroxysmal atrial fibrillation.

Key words

Catheter ablation - anticoagulation - Coumadin - DOAK

Full Text

References

Literatur
1 Sorgente A, Chierchia GB, de Asmundis C et al. Complications of atrial fibrillation ablation: when prevention is better than cure. Europace 2011; 13: 1526-1532
2 Winkle RA, Mead RH, Engel G, Patrawala RA. Long term results of atrial fibrillation ablation: The importance of all initial ablation failures undergoing a repeat ablation. Am Heart J 2011; 162: 193-200
3 Lip GY, Nieuwlaat R, Pisters R et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor based approach: The Euro Heart Survey on Atrial Fibrillation. Chest 2010; 137: 263-272
4 Camm AJ, Lip GY, De Caterina R et al. 2012 focused update of the ESC guidelines for the management of atrial fibrillation. Eur Heart J 2012; 33: 2719-2747
5 Calkins H, Kuck KH, Cappato R et al. 2012 HRS/EHRA/ECAS Expert Consensus Statement on Catheter and Surgical Ablation of Atrial Fibrillation: recommendations for patient selection, procedural techniques, patient management and follow up, definitions, endpoints, and research trial design. Europace 2012; 14: 1385-1385
6 Calkins H, Brugada J, Packer DL et al. 2012 HRS/EHRA/ECAS Expert Consensus Statement on Catheter and Surgical Ablation of Atrial Fibrillation: recommendations for personnel, policy, procedures and follow-up. Heart Rhythm 2007; 4: 1-1
7 Camm AJ et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: An update of the 2010 ESC Guidelines for the management of atrial fibrillation. Europace 2012; 14: 1385-1413
8 Wann LS, Curtis AB, January CT et al. 2011 ACCF/AHA/HRS Focused Update on the Management of Patients With Atrial Fibrillation (Updating the 2006 Guideline) A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Heart Rhythm 2011; 8: 157-176
9 Verma A, Macle L, Cox J et al. Canadian Cardiovascular Society atrial fibrillation guidelines 2010: catheter ablation for atrial fibrillation/flutter. Can J Cardiol 2011; 27: 60-66
10 Marrouche NF, Wilber D, Hindricks G et al. Association of Atrial Tissue Fibrosis Identified by Delayed Enhancement MRI and Atrial Fibrillation Catheter Ablation. The DECAAF Study. JAMA 2014; 311: 498-506
11 Page SP, Siddiqui MS, Finlay M et al. Catheter ablation for atrial fibrillation on uninterrupted warfarin: can it be done without echo guidance?. J Cardiovasc Electrophysiol 2011; 22: 265-270
12 Packer DL et al. HRS CABANA Investigators Meeting. 2013;
13 Packer DL, Kowal RC, Wheelan KR et al. Cryoballoon ablation of pulmonary veins for paroxysmal atrial fibrillation: first results of the North American Arctic Front (STOP AF) pivotal trial. J Am Coll Cardiol 2013; 61: 1713-1723
14 Kuck K et al. GAP-AF study helps to define optimal approach to ablation/ SARA study shows ablation superior to drugs for patients with persistent AF. ESC 2013; Athens
15 Kirchhof P, Fetsch T, Hanrath P et al. Targeted pharmacological reversal of electrical remodeling after Cardioversion – rationale and design of the Flecainide Short-Long (Flec-SL) trial. Am Heart J 2005; 150: 899-899
16 Stabile G, Bertaglia E, Senatore G et al. Catheter ablation treatment in patients with drug-refractory atrial fibrillation: a prospective, multi-centre, randomized, controlled study (Catheter Ablation For The Cure Of Atrial Fibrillation Study). Eur Heart J 2006; 27: 216-221
17 Lakkireddy D, Reddy YM, Di Biase L et al. Feasibility and safety of dabigatran versus warfarin for periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial fibrillation: results from a multicenter prospective register. J Am Coll Cardiol 2012; 59: 1168-1174
18 Lloyd-Jones DM, Wang TJ, Leip EP et al. Lifetime risk for development of atrial fibrillation: The Framingham Heart Study. Circulation 2004; 110: 1042-1046
19 Garnock-Jones KP et al. Dabigatran etexilate. A review of its use in the prevention of stroke and systemic embolism in patients with atrial fibrillation. Am J Cardiovasc Drugs 2011; 11: 57-72
20 Eitel C, Koch J, Sommer P et al. Novel oral anticoagulants in a real-world cohort of patients undergoing catheter ablation of atrial fibrillation. Europace 2013; 15: 1587-1593
21 Sorgente A, Chierchia GB, de Asmundis C et al. Complications of atrial fibrillation ablation: when prevention is better than cure. Europace 2011; 13: 1526-1532
22 Connolly SJ, Ezekowitz MD, Yusuf S et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Eng J Med 2009; 361: 1139-1151
23 Connolly SJ, Ezekowitz MD, Yusuf S et al. Newly identified events in the RE-LY® trial. N Engl J Med 2010; 363: 1875-1876
24 Giugliano RP, Ruff CT, Braunwald E et al. Edoxaban versus Warfarin in patients with atrial fibrillation. N Engl J Med 2013; 369: 2093-2104
25 Granger CB et al. Apixaban versus Warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365: 981-992
26 Patel MR, Mahaffey KW, Garg J et al. Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation. N Engl J Med 2011; 365: 883-891
27 Themistoclakis S, Corrado A, Marchlinski FE et al. The Risk of Thromboembolism and Need for Oral Anticoagulation After Successful Atrial Fibrillation Ablation. J Am Coll Cardiol 2010; 55: 735-743
28 Bunch TJ et al. Patients Treated with Catheter Ablation for Atrial Fibrillation Have Long-Term Rates of Death, Stroke and Dementia Similar to Patients without Atrial Fibrillation. J Cardiovasc Electrophysiol 2011; 22: 839-845
29 Bunch TJ, Crandall BG, Weiss JP et al. Atrial fibrillation ablation patients have long-term stroke rates similar to patients without atrial fibrillation regardless of CADS2 score. Heart Rhythm 2013; 10: 1272-1277
30 Winke RA, Mead RH, Engel G et al. The use of dabigatran immediately after atrial fibrillation ablation. J Cardiovasc Electrophysiol 2012; 23: 264-268
31 Providência R, Albenque JP, Combes S et al. Safety and efficacy of dabigatran versus warfarin in patients undergoing catheter ablation of atrial fibrillation: a systematic review and meta-analysis. Heart 2014; 100: 324-335
32 Reddy VY, Doshi SK, Sievert H et al. Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial. Circulation 2013; 127: 720-729
33 Holmes DR et al. Randomized Trial of LAA Closure vs Warfarin for Stroke/ Thromboembolic Prevention in Patients with Non-valvular Atrial Fibrillation (PREVAIL). ACC 2013; San Francisco